Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein PS, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A.

Leukemia. 2019 Nov 22. doi: 10.1038/s41375-019-0650-2. [Epub ahead of print]

PMID:
31758088
2.

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.

Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS.

Oncologist. 2019 Nov;24(11):1416-1419. doi: 10.1634/theoncologist.2018-0686. Epub 2019 Aug 23.

3.

Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.

Regan S, Yang X, Finnberg NK, El-Deiry WS, Pu JJ.

Cancer Biol Ther. 2019;20(11):1389-1397. doi: 10.1080/15384047.2019.1647055. Epub 2019 Aug 18.

PMID:
31423878
4.

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A.

J Immunother Cancer. 2019 May 22;7(1):136. doi: 10.1186/s40425-019-0599-8.

5.

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL.

CA Cancer J Clin. 2019 Jul;69(4):305-343. doi: 10.3322/caac.21560. Epub 2019 May 22. Review.

6.

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC).

El-Deiry WS, Winer A, Slifker M, Taylor S, Adamson BJS, Meropol NJ, Ross EA.

Front Oncol. 2019 Mar 14;9:142. doi: 10.3389/fonc.2019.00142. eCollection 2019.

7.

Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein P, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A.

Leukemia. 2019 Oct;33(10):2429-2441. doi: 10.1038/s41375-019-0454-4. Epub 2019 Mar 26. Erratum in: Leukemia. 2019 Nov 22;:.

PMID:
30914792
8.

TRAIL pathway targeting therapeutics.

Ralff MD, El-Deiry WS.

Expert Rev Precis Med Drug Dev. 2018;3(3):197-204. doi: 10.1080/23808993.2018.1476062. Epub 2018 May 28.

9.

Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic.

Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Slifker M, Saltzberg PD, Bubes N, Anari FM, Kasireddy V, Varshavsky A, Liu Y, Ross EA, El-Deiry WS.

Front Oncol. 2019 Jan 17;8:652. doi: 10.3389/fonc.2018.00652. eCollection 2018.

10.

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.

Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE.

Clin Cancer Res. 2019 Apr 1;25(7):2305-2313. doi: 10.1158/1078-0432.CCR-18-2572. Epub 2018 Dec 17.

PMID:
30559168
11.

ONC201: a new treatment option being tested clinically for recurrent glioblastoma.

Ralff MD, Lulla AR, Wagner J, El-Deiry WS.

Transl Cancer Res. 2017 Oct;6(Suppl 7):S1239-S1243. doi: 10.21037/tcr.2017.10.03.

12.

Bcl-2 Protein Targeting by the p53/p21 Complex-Letter.

Hernandez Borrero LJ, Sikder R, Lulla A, Gokare P, Del Valle PR, Tian X, Zhang S, Abbosh PH, El-Deiry WS.

Cancer Res. 2018 May 15;78(10):2770-2771. doi: 10.1158/0008-5472.CAN-17-2556. Epub 2018 Apr 27. No abstract available.

13.

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.

Lev A, Lulla AR, Ross BC, Ralff MD, Makhov PB, Dicker DT, El-Deiry WS.

Mol Cancer Res. 2018 May;16(5):754-766. doi: 10.1158/1541-7786.MCR-17-0614. Epub 2018 Mar 27.

14.

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.

Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS.

J Clin Invest. 2018 Jun 1;128(6):2325-2338. doi: 10.1172/JCI96711. Epub 2018 Apr 30.

15.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

16.

Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling.

Matthew EM, Yang Z, Peri S, Andrake M, Dunbrack R, Ross E, El-Deiry WS.

Neoplasia. 2018 Mar;20(3):244-255. doi: 10.1016/j.neo.2018.01.004. Epub 2018 Feb 12.

17.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

18.
19.

Role of Dopamine Receptors in the Anticancer Activity of ONC201.

Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS.

Neoplasia. 2018 Jan;20(1):80-91. doi: 10.1016/j.neo.2017.10.002. Epub 2017 Dec 5.

20.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.

21.

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.

Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL.

Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17.

22.

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS.

Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. eCollection 2017 Oct 10.

23.

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.

Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS.

Cancer Res. 2017 Dec 15;77(24):6902-6913. doi: 10.1158/0008-5472.CAN-17-1767. Epub 2017 Oct 23.

24.

Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures.

Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW 4th, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS.

Oncotarget. 2017 Aug 5;8(40):66747-66757. doi: 10.18632/oncotarget.19965. eCollection 2017 Sep 15.

25.

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2017 Sep 2;18(9):694-704. doi: 10.1080/15384047.2017.1364323. Epub 2017 Sep 8.

26.

Circulating tumor cells: silent predictors of metastasis.

Zhou L, Dicker DT, Matthew E, El-Deiry WS, Alpaugh RK.

F1000Res. 2017 Aug 14;6. pii: F1000 Faculty Rev-1445. doi: 10.12688/f1000research.11313.1. eCollection 2017. Review.

27.

P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.

Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS.

Sci Rep. 2017 Aug 29;7(1):9711. doi: 10.1038/s41598-017-09859-x.

28.

MMR-deficiency and BRCA2/EGFR/NTRK mutations.

Gokare P, Lulla AR, El-Deiry WS.

Aging (Albany NY). 2017 Aug 3;9(8):1849-1850. doi: 10.18632/aging.101275. No abstract available.

29.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.

Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS.

PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.

30.

Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth.

Richardson C, Zhang S, Hernandez Borrero LJ, El-Deiry WS.

Cell Cycle. 2017 Sep 17;16(18):1719-1725. doi: 10.1080/15384101.2017.1356514. Epub 2017 Jul 27.

31.

CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA.

Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS.

Cell Cycle. 2018;17(5):557-567. doi: 10.1080/15384101.2017.1346762. Epub 2018 Feb 19.

32.

Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?

El-Deiry WS, Taylor B, Neal JW.

Am Soc Clin Oncol Educ Book. 2017;37:e8-e15. doi: 10.14694/EDBK_175524.

33.

Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.

Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS.

Cancer Biol Ther. 2017 Sep 2;18(9):651-654. doi: 10.1080/15384047.2017.1356506. Epub 2017 Jul 20.

34.

The tuberous sclerosis complex gets fatter.

Gokare P, El-Deiry WS.

Oncotarget. 2017 Jun 27;8(26):41780-41781. doi: 10.18632/oncotarget.18436. No abstract available.

35.

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.

Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS.

Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.

36.

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS.

Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10.

37.

The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS.

Cell Cycle. 2017 Jun 18;16(12):1193-1200. doi: 10.1080/15384101.2017.1320005. Epub 2017 May 9.

38.

Tissue TGF-β expression following conventional radiotherapy and pulsed low-dose-rate radiation.

Meyer JE, Finnberg NK, Chen L, Cvetkovic D, Wang B, Zhou L, Dong Y, Hallman MA, Ma CC, El-Deiry WS.

Cell Cycle. 2017 Jun 18;16(12):1171-1174. doi: 10.1080/15384101.2017.1317418. Epub 2017 May 9.

39.

Impact of perineural invasion on survival in node negative colon cancer.

Mirkin KA, Hollenbeak CS, Mohamed A, Jia Y, El-Deiry WS, Messaris E.

Cancer Biol Ther. 2017 Sep 2;18(9):740-745. doi: 10.1080/15384047.2017.1323602. Epub 2017 May 5.

40.

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.

Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS.

Mol Cancer Ther. 2017 Jul;16(7):1290-1298. doi: 10.1158/1535-7163.MCT-17-0121. Epub 2017 Apr 19.

41.

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM.

Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22.

42.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

43.

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ.

Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.

44.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
45.

p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy.

El-Deiry WS.

Cancer Res. 2016 Sep 15;76(18):5189-91. doi: 10.1158/0008-5472.CAN-16-2055. Review.

46.

Discovery and clinical introduction of first-in-class imipridone ONC201.

Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.

Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Review.

47.

Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.

Tan CR, Zhou L, El-Deiry WS.

Curr Colorectal Cancer Rep. 2016 Jun;12(3):151-161. Epub 2016 Apr 7.

48.

Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).

Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS.

Clin Cancer Res. 2016 Dec 15;22(24):6192-6203. Epub 2016 Jun 15.

49.

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.

Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS.

Sci Signal. 2016 Feb 16;9(415):ra18. doi: 10.1126/scisignal.aac4374.

50.

Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.

Allen JE, Crowder RN, El-Deiry WS.

PLoS One. 2016 Feb 10;11(2):e0149365. doi: 10.1371/journal.pone.0149365. eCollection 2016. No abstract available.

Supplemental Content

Loading ...
Support Center